Effective GDNF brain delivery using microspheres—A promising strategy for Parkinson's disease

The rat brain in stereotaxic coordinates

Palkovits, M. (1983) · Neuropeptides · doi:10.1016/0143-4179(83)90049-5 · Cited by 28,959

The Rat Brain in Stereotaxic Coordinates

Paxinos, G., & Watson, C. (1983) · Elsevier eBooks · doi:10.1016/c2009-0-63235-9 · Cited by 28,585

GDNF: a Glial Cell Line-Derived Neurotrophic Factor for Midbrain Dopaminergic Neurons

Lin, L.-F. H., Doherty, D. H., Lile, J. D., Bektesh, S. L., & Collins, F. (1993) · Science · doi:10.1126/science.8493557 · Cited by 3,206

Direct brain infusion of glial cell line–derived neurotrophic factor in Parkinson disease

Gill, S. S., Patel, N. K., Hotton, G. R., O'Sullivan, K., McCarter, R., Bunnage, M., Brooks, D. J., Svendsen, C. N., & Heywood, P. (2003) · Nature Medicine · doi:10.1038/nm850 · Cited by 1,290

Neurodegeneration Prevented by Lentiviral Vector Delivery of GDNF in Primate Models of Parkinson's Disease

Kordower, J. H., Emborg, M. E., Bloch, J., Ma, S. Y., Chu, Y., Leventhal, L., McBride, J. L., Chen, E., Palfi, S., Roitberg, B. Z., et al. (2000) · Science · doi:10.1126/science.290.5492.767 · Cited by 1,251

Randomized controlled trial of intraputamenal glial cell line–derived neurotrophic factor infusion in Parkinson disease

Lang, A. E., Gill, S., Patel, N., Lozano, A., Nutt, J. G., Penn, R., Brooks, D. J., Hotton, G. R., Moro, E., Heywood, P., et al. (2006) · Annals of Neurology · doi:10.1002/ana.20737 · Cited by 987

Characterization of Behavioral and Neurodegenerative Changes Following Partial Lesions of the Nigrostriatal Dopamine System Induced by Intrastriatal 6-Hydroxydopamine in the Rat

Kirik, D., Rosenblad, C., & Björklund, A. (1998) · Experimental Neurology · doi:10.1006/exnr.1998.6848 · Cited by 663

Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line—derived neurotrophic factor

Slevin, J. T., Gerhardt, G. A., Smith, C. D., Gash, D. M., Kryscio, R. J., & Young, B. A. (2005) · Journal of neurosurgery · doi:10.3171/jns.2005.102.2.0216 · Cited by 474

Intraputamenal infusion of glial cell line–derived neurotrophic factor in PD: A two‐year outcome study

Patel, N. K., Bunnage, M., Plaha, P., Svendsen, C. N., Heywood, P. G., & Gill, S. S. (2005) · Annals of Neurology · doi:10.1002/ana.20374 · Cited by 384

Biocompatibility of implantable synthetic polymeric drug carriers: focus on brain biocompatibility

Fournier, E., Passirani, C., Montero‐Menei, C. N., & Benoît, J. (2003) · Biomaterials · doi:10.1016/s0142-9612(03)00161-3 · Cited by 353

PLGA-based nanoparticles: An overview of biomedical applications

Danhier, F., Ansorena, E., Silva, J. M., Coco, R., Breton, A. L., & Véronique Préat, A. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.01.043 · Cited by 4,006

GDNF, NGF and BDNF as Therapeutic Options for Neurodegeneration

Allen, S. J., Watson, J. J., Shoemark, D. K., Barua, N. U., & Patel, N. K. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.01.004 · Cited by 820

Targeted therapy in chronic diseases using nanomaterial-based drug delivery vehicles

Singh, A. P., Biswas, A., Shukla, A., & Maiti, P. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0068-3 · Cited by 645

Current and Novel Polymeric Biomaterials for Neural Tissue Engineering

Boni, R., Ali, A., Shavandi, A., & Clarkson, A. N. (2018) · Journal of Biomedical Science · doi:10.1186/s12929-018-0491-8 · Cited by 439

Biomaterials for promoting brain protection, repair and regeneration

Orive, G., Anitua, E., Pedraz, J. L., & Emerich, D. F. (2009) · Nature reviews. Neuroscience · doi:10.1038/nrn2685 · Cited by 421

Stem cell technology for neurodegenerative diseases

Lunn, J. S., Sakowski, S. A., Hur, J., & Feldman, E. L. (2011) · Annals of Neurology · doi:10.1002/ana.22487 · Cited by 275

Sustained release of VEGF through PLGA microparticles improves vasculogenesis and tissue remodeling in an acute myocardial ischemia–reperfusion model

Formiga, F. R., Pelacho, B., Garbayo, E., Abizanda, G., Gavira, J. J., Simón‐Yarza, T., Mazo, M. M., Tamayo, E., Jauquicoa, C., & Ortíz-de-Solórzano, C. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.07.097 · Cited by 210

Potential of endogenous regenerative technology for in situ regenerative medicine☆

Anitua, E., Sánchez, M., & Orive, G. (2010) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.01.001 · Cited by 208

Novel Focused Ultrasound Gene Therapy Approach Noninvasively Restores Dopaminergic Neuron Function in a Rat Parkinson’s Disease Model

Mead, B. P., Kim, N., Miller, G. W., Hodges, D., Mastorakos, P., Klibanov, A. L., Mandell, J. W., Hirsh, J., Suk, J. S., Hanes, J., et al. (2017) · Nano Letters · doi:10.1021/acs.nanolett.7b00616 · Cited by 151

Non-invasive, neuron-specific gene therapy by focused ultrasound-induced blood-brain barrier opening in Parkinson's disease mouse model

Lin, C., Hsieh, H.-Y., Chen, C., Wu, S.-R., Tsai, C.-H., Huang, C.-Y., Hua, M., Wei, K., Yeh, C., & Liu, H.-L. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.05.052 · Cited by 156

Advances in Parkinson’s Disease: 200 Years Later

del Rey, N. L., Quiroga‐Varela, A., Garbayo, E., Carballo‐Carbajal, I., Fernández‐Santiago, R., Monje, M. H. G., Trigo‐Damas, I., Blanco‐Prieto, M. J., & Blesa, J. (2018) · Frontiers in Neuroanatomy · doi:10.3389/fnana.2018.00113 · Cited by 146

Awareness and current knowledge of Parkinson’s disease: a neurodegenerative disorder

Khan, A. U., Akram, M., Daniyal, M., & Zainab, R. (2018) · International Journal of Neuroscience · doi:10.1080/00207454.2018.1486837 · Cited by 151

Intranasal Administration of TAT-Conjugated Lipid Nanocarriers Loading GDNF for Parkinson’s Disease

Hernando, S., Herrán, E., Figueiro‐Silva, J., Pedraz, J. L., Igartúa, M., Carro, E., & Hernández, R. M. (2017) · Molecular Neurobiology · doi:10.1007/s12035-017-0728-7 · Cited by 137

Nanomedicine and drug delivery systems in cancer and regenerative medicine

Garbayo, E., Pascual‐Gil, S., Rodríguez‐Nogales, C., Saludas, L., de Mendoza, A. E., & Blanco‐Prieto, M. J. (2020) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1637 · Cited by 140

The therapeutic potential of human multipotent mesenchymal stromal cells combined with pharmacologically active microcarriers transplanted in hemi-parkinsonian rats

Delcroix, G. J.-R., Garbayo, E., Sindji, L., Thomas, O., Vanpouille‐Box, C., Schiller, P. C., & Montero‐Menei, C. N. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2010.10.041 · Cited by 127

Repairing the parkinsonian brain with neurotrophic factors

Aron, L., & Klein, R. (2010) · Trends in Neurosciences · doi:10.1016/j.tins.2010.11.001 · Cited by 127

From Molecular to Nanotechnology Strategies for Delivery of Neurotrophins: Emphasis on Brain-Derived Neurotrophic Factor (BDNF)

Géral, C., Angelova, A., & Lesieur, S. (2013) · Pharmaceutics · doi:10.3390/pharmaceutics5010127 · Cited by 126

Injectable alginate hydrogel loaded with GDNF promotes functional recovery in a hemisection model of spinal cord injury

Ansorena, E., Berdt, P. D., Učakar, B., Simón‐Yarza, T., Jacobs, D., Schakman, O., Jankovski, A., Deumens, R., Blanco‐Prieto, M. J., Véronique Préat, A., et al. (2013) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2013.07.045 · Cited by 109

Retinal ganglion cells survival in a glaucoma model by GDNF/Vit E PLGA microspheres prepared according to a novel microencapsulation procedure

Checa-Casalengua, P., Jiang, C., Bravo‐Osuna, I., Tucker, B. A., Molina-Martínez, I. T., Young, M. J., & Herrero‐Vanrell, R. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.06.023 · Cited by 106

Biomaterial-based drug delivery systems for the controlled release of neurotrophic factors

Mohtaram, N. K., Montgomery, A., & Willerth, S. M. (2013) · Biomedical Materials · doi:10.1088/1748-6041/8/2/022001 · Cited by 104

Cell and biomolecule delivery for tissue repair and regeneration in the central nervous system

Donaghue, I. E., Tam, R. Y., Sefton, M. V., & Shoichet, M. S. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.05.040 · Cited by 102

GDNF-based therapies, GDNF-producing interneurons, and trophic support of the dopaminergic nigrostriatal pathway. Implications for Parkinson’s disease

de Tassigny, X. D., Pascual, A., & López‐Barneo, J. (2015) · Frontiers in Neuroanatomy · doi:10.3389/fnana.2015.00010 · Cited by 99

The therapeutic potential of IGF-I in skeletal muscle repair

Song, Y., Song, J. L., Delafontaine, P., & Godard, M. P. (2013) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2013.03.004 · Cited by 102

The administration of BDNF and GDNF to the brain via PLGA microparticles patterned within a degradable PEG‐based hydrogel: Protein distribution and the glial response

Lampe, K. J., Kern, D. S., Mahoney, M. J., & Bjugstad, K. B. (2011) · Journal of Biomedical Materials Research Part A · doi:10.1002/jbm.a.33011 · Cited by 102

Retinoic acid-loaded polymeric nanoparticles induce neuroprotection in a mouse model for Parkinson's disease

Esteves, M., Cristóvão, A. C., Saraiva, T., Rocha, S. M., Baltazar, G., Ferreira, L., & Bernardino, L. (2015) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2015.00020 · Cited by 88

Drug development in Parkinson's disease: From emerging molecules to innovative drug delivery systems

Garbayo, E., Ansorena, E., & Blanco‐Prieto, M. J. (2013) · Maturitas · doi:10.1016/j.maturitas.2013.05.019 · Cited by 83

Tackling Cell Transplantation Anoikis: An Injectable, Shape Memory Cryogel Microcarrier Platform Material for Stem Cell and Neuronal Cell Growth

Newland, B., Welzel, P. B., Newland, H., Renneberg, C., Kolar, P., Tsurkan, M. V., Rosser, A., Freudenberg, U., & Werner, C. (2015) · Small · doi:10.1002/smll.201500898 · Cited by 83

Drug Delivery Systems for Imaging and Therapy of Parkinson';s Disease

Silindir‐Gunay, M., Özer, A. Y., & Chalon, S. (2015) · Current Neuropharmacology · doi:10.2174/1570159x14666151230124904 · Cited by 83

Glial cell line‐derived neurotrophic factor–secreting genetically modified human bone marrow‐derived mesenchymal stem cells promote recovery in a rat model of Parkinson's disease

Glavaski‐Joksimovic, A., Virág, T., Mangatu, T. A., McGrogan, M. P., Wang, X. S., & Bohn, M. C. (2010) · Journal of Neuroscience Research · doi:10.1002/jnr.22435 · Cited by 77

Can dendrimer based nanoparticles fight neurodegenerative diseases? Current situation versus other established approaches

Mignani, S. M., Bryszewska, M. J., Zabłocka, M., Klajnert‐Maculewicz, B., Cladera, J., Shcharbin, D., & Majoral, J. (2016) · Progress in Polymer Science · doi:10.1016/j.progpolymsci.2016.09.006 · Cited by 77

Delivery of Alginate Scaffold Releasing Two Trophic Factors for Spinal Cord Injury Repair

Grulova, I., Slovinská, L., Blaško, J., Devaux, S., Wisztorski, M., Salzet, M., Fournier, I., Kryukov, O., Cohen, S., & Čı́žková, D. (2015) · Scientific Reports · doi:10.1038/srep13702 · Cited by 77

In vivo administration of VEGF- and GDNF-releasing biodegradable polymeric microspheres in a severe lesion model of Parkinson’s disease

Herrán, E., Ruíz-Ortega, J. Á., Aristieta, A., Igartúa, M., Requejo, C., Lafuente, J. V., Ugedo, L., Pedraz, J. L., & Hernández, R. M. (2013) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2013.03.034 · Cited by 68

PEGylated-PLGA microparticles containing VEGF for long term drug delivery

Simón‐Yarza, T., Formiga, F. R., Tamayo, E., Pelacho, B., Prósper, F., & Blanco‐Prieto, M. J. (2012) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2012.07.006 · Cited by 66

Nanoparticle-mediated growth factor delivery systems: A new way to treat Alzheimer's disease

Lauzon, M.-A., Daviau, A., Marcos, B., & Faucheux, N. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.03.024 · Cited by 66

Brain delivery of microencapsulated GDNF induces functional and structural recovery in parkinsonian monkeys

Garbayo, E., Ansorena, E., Lana, H., Carmona‐Abellán, M., Marcilla, I., Lanciego, J. L., Luquín, M. R., & Blanco‐Prieto, M. J. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.09.015 · Cited by 65

Collagen for brain repair: therapeutic perspectives

Humpel, C., & Uçar, B. (2018) · Neural Regeneration Research · doi:10.4103/1673-5374.230273 · Cited by 65

A novel polymeric drug delivery system for localized and sustained release of tacrolimus (FK506)

Tajdaran, K., Shoichet, M. S., Gordon, T., & Borschel, G. H. (2015) · Biotechnology and Bioengineering · doi:10.1002/bit.25598 · Cited by 64

Increased antiparkinson efficacy of the combined administration of VEGF- and GDNF-loaded nanospheres in a partial lesion model of Parkinson’s disease

Hernández, R. M., Herrán, E., Requejo, C., Ruíz-Ortega, J. Á., Aristieta, A., Igartúa, M., Bengoetxea, H., Ugedo, L., Pedraz, J. L., & Lafuente, J. V. (2014) · International Journal of Nanomedicine · doi:10.2147/ijn.s61940 · Cited by 63

VEGF-releasing biodegradable nanospheres administered by craniotomy: A novel therapeutic approach in the APP/Ps1 mouse model of Alzheimer's disease

Herrán, E., Pérez‐González, R., Igartúa, M., Pedraz, J. L., Carro, E., & Hernández, R. M. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.04.028 · Cited by 69

TPP ionically cross-linked chitosan/PLGA microspheres for the delivery of NGF for peripheral nerve system repair

Zeng, W., Hui, H., Liu, Z., Chang, Z., Wang, M., He, B., & Hao, D. (2021) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2021.117684 · Cited by 60

Fibrin Gels Containing GDNF Microspheres Increase Axonal Regeneration After Delayed Peripheral Nerve Repair

Wood, M. D., Gordon, T., Kim, H. S., Szynkaruk, M., Phua, P. D., Lafontaine, C., Kemp, S. W. P., Shoichet, M. S., & Borschel, G. H. (2012) · Regenerative Medicine · doi:10.2217/rme.12.105 · Cited by 59

A drug delivery hydrogel system based on activin B for Parkinson's disease

Li, J., Darabi, M.-A., Gu, J., Shi, J., Xue, J., Huang, L. H., Liu, Y., Zhang, L., Liu, N., Zhong, W., et al. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.06.016 · Cited by 56

Injectables and Depots to Prolong Drug Action of Proteins and Peptides

Ibeanu, N., Egbu, R., Onyekuru, L., Javaheri, H., Khaw, P. T., Williams, G. R., Brocchini, S., & Awwad, S. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12100999 · Cited by 56

Brain aging and Parkinson’s disease: New therapeutic approaches using drug delivery systems

Rodríguez‐Nogales, C., Garbayo, E., Carmona‐Abellán, M., Luquín, M. R., & Blanco‐Prieto, M. J. (2015) · Maturitas · doi:10.1016/j.maturitas.2015.11.009 · Cited by 54

Nanomedicine and drug delivery: A comprehensive review of applications and challenges

Singh, K., Singhal, S., Pahwa, S., Sethi, V. A., Sharma, S., Singh, P., Kale, R. D., Ali, S. W., & Sagadevan, S. (2024) · Nano-Structures & Nano-Objects · doi:10.1016/j.nanoso.2024.101403 · Cited by 50

Advances in Nanomedicine for the Treatment of Alzheimer’s and Parkinson’s Diseases

Hernando, S., Gartziandia, O., Herrán, E., Pedraz, J. L., Igartúa, M., & Hernández, R. M. (2016) · Nanomedicine · doi:10.2217/nnm-2016-0019 · Cited by 48

Optimising the controlled release of dexamethasone from a new generation of PLGA-based microspheres intended for intravitreal administration

Villanueva, J. R., Bravo‐Osuna, I., Herrero‐Vanrell, R., Molina-Martínez, I. T., & Guzmán, M. (2016) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2016.03.012 · Cited by 48

Long‐term neuroprotection and neurorestoration by glial cell‐derived neurotrophic factor microspheres for the treatment of Parkinson's disease

Garbayo, E., Ansorena, E., Lanciego, J. L., Blanco‐Prieto, M. J., & Aymerich, M. S. (2011) · Movement Disorders · doi:10.1002/mds.23793 · Cited by 47

Exploring the role of polymers to overcome ongoing challenges in the field of extracellular vesicles

Simon, L., Lapinte, V., & Morille, M. (2023) · Journal of Extracellular Vesicles · doi:10.1002/jev2.12386 · Cited by 47

The role of growth factors as a therapeutic approach to demyelinating disease

Huang, Y., & Dreyfus, C. F. (2016) · Experimental Neurology · doi:10.1016/j.expneurol.2016.02.023 · Cited by 46

Neuroprotective Effects of Antidepressants via Upregulation of Neurotrophic Factors in the MPTP Model of Parkinson’s Disease

Shadfar, S., Kim, Y.-G., Katila, N., Neupane, S., Ojha, U., Bhurtel, S., Srivastav, S., Jeong, G., Park, P., Hong, J. T., et al. (2016) · Molecular Neurobiology · doi:10.1007/s12035-016-0342-0 · Cited by 42

Microspheres as intraocular therapeutic tools in chronic diseases of the optic nerve and retina

Bravo‐Osuna, I., Andrés‐Guerrero, V., Arranz-Romera, A., Esteban-Pérez, S., Molina-Martínez, I. T., & Herrero‐Vanrell, R. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.01.007 · Cited by 42

Effects of intrastriatal GDNF on the response of dopamine neurons to 6-hydroxydopamine: Time course of protection and neurorestoration

Cohen, A. D., Zigmond, M. J., & Smith, A. D. (2010) · Brain Research · doi:10.1016/j.brainres.2010.11.006 · Cited by 40

Double hydrophilic polyphosphoester containing copolymers as efficient templating agents for calcium carbonate microparticles

Ergül, Z., Debuigne, A., Calvignac, B., Boury, F., & Jérôme, C. (2015) · Journal of Materials Chemistry B · doi:10.1039/c5tb00887e · Cited by 38

Synthesis of ROS scavenging microspheres from a dopamine containing poly(β-amino ester) for applications for neurodegenerative disorders

Newland, B., Wolff, P., Zhou, D., Wang, W., Zhang, H., Rosser, A., Wang, W., & Werner, C. (2016) · Biomaterials Science · doi:10.1039/c5bm00542f · Cited by 38

Diagnostic and Therapeutic Uses of Nanomaterials in the Brain

Garbayo, E., de Mendoza, A. E., & Blanco‐Prieto, M. J. (2014) · Current Medicinal Chemistry · doi:10.2174/0929867321666140815124246 · Cited by 38

The Effects of Glial Cell Line-Derived Neurotrophic Factor after Spinal Cord Injury

Rosich, K., Hanna, B. F., Ibrahim, R. K., Hellenbrand, D. J., & Hanna, A. (2017) · Journal of Neurotrauma · doi:10.1089/neu.2017.5175 · Cited by 37

An engineered biocompatible drug delivery system enhances nerve regeneration after delayed repair

Tajdaran, K., Gordon, T., Wood, M. D., Shoichet, M. S., & Borschel, G. H. (2015) · Journal of Biomedical Materials Research Part A · doi:10.1002/jbm.a.35572 · Cited by 35

Adipose-derived stem cells combined with Neuregulin-1 delivery systems for heart tissue engineering

Díaz-Herráez, P., Garbayo, E., Simón‐Yarza, T., Formiga, F. R., Prósper, F., & Blanco‐Prieto, M. J. (2013) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2013.03.022 · Cited by 34

Nanotherapeutic strategies for the treatment of neurodegenerative diseases

Huang, M., Gu, X. Q., & Gao, X. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-814001-7.00013-5 · Cited by 34

Recent Strategies for Targeted Brain Drug Delivery

Ogawa, K., Kato, N., & Kawakami, S. (2020) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.c20-00041 · Cited by 34

Interplay of BDNF and GDNF in the Mature Spinal Somatosensory System and Its Potential Therapeutic Relevance

Ferrini, F., Salio, C., Boggio, E. M., & Merighi, A. (2020) · Current Neuropharmacology · doi:10.2174/1570159x18666201116143422 · Cited by 34

Prospects for polymer therapeutics in Parkinson's disease and other neurodegenerative disorders

Newland, B., Newland, H., Werner, C., Rosser, A., & Wang, W. (2015) · Progress in Polymer Science · doi:10.1016/j.progpolymsci.2014.12.002 · Cited by 35

Biomaterial based strategies to reconstruct the nigrostriatal pathway in organotypic slice co-cultures

Uçar, B., Kajtez, J., Foidl, B. M., Eigel, D., Werner, C., Long, K. R., Emnéus, J., Bizeau, J., Lomora, M., Pandit, A. S., et al. (2020) · Acta Biomaterialia · doi:10.1016/j.actbio.2020.11.035 · Cited by 33

New non-oral drug delivery systems for Parkinson's disease treatment

Md, S., Haque, S., Sahni, J. K., Baboota, S., & Ali, J. (2011) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2011.556616 · Cited by 33

Functional motor recovery is improved due to local placement of GDNF microspheres after delayed nerve repair

Wood, M. D., Gordon, T., Kemp, S. W. P., Liu, E. H., Kim, H. S., Shoichet, M. S., & Borschel, G. H. (2012) · Biotechnology and Bioengineering · doi:10.1002/bit.24800 · Cited by 32

Therapeutic efficacy of glial cell-derived neurotrophic factor loaded collagen scaffolds in ex vivo organotypic brain slice Parkinson’s disease models

Uçar, B., & Humpel, C. (2019) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2019.04.012 · Cited by 32

Biodegradation and heart retention of polymeric microparticles in a rat model of myocardial ischemia

Formiga, F. R., Garbayo, E., Díaz-Herráez, P., Abizanda, G., Simón‐Yarza, T., Tamayo, E., Prósper, F., & Blanco‐Prieto, M. J. (2013) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2013.02.017 · Cited by 32

On the Right Track to Treat Movement Disorders: Promising Therapeutic Approaches for Parkinson’s and Huntington’s Disease

Troncoso-Escudero, P., Sepúlveda, D., Pérez-Arancibia, R., Parra, A. V., Arcos, J., Grünenwald, F., & Vidal, R. L. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.571185 · Cited by 31

Neurotrophic Factors and Neurodegenerative Diseases

Ruozi, B., Belletti, D., Bondioli, L., Vita, A. D., Forni, F., Vandelli, M. A., & Tosi, G. (2012) · International review of neurobiology · doi:10.1016/b978-0-12-386986-9.00009-0 · Cited by 29

Long-term exposure to GDNF induces dephosphorylation of Ret, AKT, and ERK1/2, and is ineffective at protecting midbrain dopaminergic neurons in cellular models of Parkinson's disease

Mesa-Infante, V., Afonso‐Oramas, D., Salas-Hernández, J., Rodríguez-Núñez, J., & Barroso‐Chinea, P. (2021) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2021.103684 · Cited by 29

Effect of different sintering methods on bioactivity and release of proteins from PLGA microspheres

Dormer, N. H., Gupta, V., Scurto, A. M., Berkland, C. J., & Detamore, M. S. (2013) · Materials Science and Engineering C · doi:10.1016/j.msec.2013.06.026 · Cited by 28

Transport of Glial Cell Line-Derived Neurotrophic Factor into Liposomes across the Blood-Brain Barrier: In Vitro and in Vivo Studies

Wu, S.-L., Li, G., Li, X., Lin, C., Yu, D., Luan, S., & Ma, C. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms15033612 · Cited by 27

Hierarchical Microplates as Drug Depots with Controlled Geometry, Rigidity, and Therapeutic Efficacy

Francesco, M. D., Primavera, R., Romanelli, D., Palomba, R., Pereira, R. C., Catelani, T., Celia, C., Marzio, L. D., Fresta, M., Mascolo, D. D., et al. (2018) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.7b19136 · Cited by 26

Retinal Cell Protection in Ocular Excitotoxicity Diseases. Possible Alternatives Offered by Microparticulate Drug Delivery Systems and Future Prospects

Villanueva, J. R., Esteban, J. M., & Villanueva, L. R. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12020094 · Cited by 26

Blood-to-Brain Drug Delivery Using Nanocarriers

Gaillard, P. J., Visser, C. C., de Boer, M., Appeldoorn, C. C. M., & Rip, J. (2013) · AAPS advances in the pharmaceutical sciences series · doi:10.1007/978-1-4614-9105-7_15 · Cited by 26

Brain Drug Delivery Systems for Neurodegenerative Disorders

Garbayo, E., Ansorena, E., & Blanco‐Prieto, M. J. (2012) · Current Pharmaceutical Biotechnology · doi:10.2174/138920112803341761 · Cited by 25

Neurotrophins as Therapeutic Agents for Parkinson’s Disease; New Chances From Focused Ultrasound?

Stefani, A., Pierantozzi, M., Cardarelli, S., Stefani, L., Cerroni, R., Conti, M., Garasto, E., Mercuri, N. B., Marini, C., & Sucapane, P. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.846681 · Cited by 23

Development and characterization of cores–shell poly(lactide-co-glycolide)-chitosan microparticles for sustained release of GDNF

Zeng, W., Liu, Z., Li, Y., Zhu, S., Ma, J., Li, W., & Gao, G. (2017) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2017.08.052 · Cited by 23

GDNF is important for striatal organization and maintenance of dopamine neurons grown in the presence of the striatum

Chermenina, M., Schouten, P., Nevalainen, N., Johansson, F., Orädd, G., & Strömberg, I. (2014) · Neuroscience · doi:10.1016/j.neuroscience.2014.04.008 · Cited by 22

Biodegradable microparticles for strictly regulating the release of neurotrophic factors

Gujral, C., Minagawa, Y., Fujimoto, K., Kitano, H., & Nakaji-Hirabayashi, T. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.03.031 · Cited by 21

Heparin-based, injectable microcarriers for controlled delivery of interleukin-13 to the brain

Schirmer, L., Hoornaert, C., Blon, D. L., Eigel, D., Neto, C., Gumbleton, M., Welzel, P. B., Rosser, A., Werner, C., Ponsaerts, P., et al. (2020) · Biomaterials Science · doi:10.1039/d0bm01249a · Cited by 23

Understanding the Potential of Genome Editing in Parkinson’s Disease

Arango, D., Bittar, A., Esmeral, N. P., Ocasión, C., Muñoz-Camargo, C., Cruz, J. C., Reyes, L. H., & Bloch, N. I. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179241 · Cited by 24

Mechanistic Insight from Preclinical Models of Parkinson’s Disease Could Help Redirect Clinical Trial Efforts in GDNF Therapy

Delgado-Minjares, K. M., Martínez‐Fong, D., Martínez-Dávila, I. A., Bañuelos, C., Gutiérrez-Castillo, M. E., Blanco-Álvarez, V. M., Cárdenas‐Aguayo, M. D. C., Luna‐Muñoz, J., Pacheco‐Herrero, M., & Soto-Rojas, L. O. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111702 · Cited by 20

Topographical Distribution of Morphological Changes in a Partial Model of Parkinson’s Disease—Effects of Nanoencapsulated Neurotrophic Factors Administration

Requejo, C., Ruíz-Ortega, J. Á., Bengoetxea, H., García-Blanco, A., Herrán, E., Aristieta, A., Igartúa, M., Ugedo, L., Pedraz, J. L., Hernández, R. M., et al. (2015) · Molecular Neurobiology · doi:10.1007/s12035-015-9234-y · Cited by 19

Controlled release of glial cell line-derived neurotrophic factor from poly(ε-caprolactone) microspheres

Agbay, A. M., Mohtaram, N. K., & Willerth, S. M. (2014) · Drug Delivery and Translational Research · doi:10.1007/s13346-013-0189-0 · Cited by 19

Eicosanoid receptor subtype‐mediated opposing regulation of TLR‐stimulated expression of astrocyte glial‐derived neurotrophic factor

Li, X., Cudaback, E., BREYER, R. M., Montine, K. S., Keene, C. D., & Montine, T. J. (2012) · The FASEB Journal · doi:10.1096/fj.11-200279 · Cited by 19

Gene Therapy Strategies for the Treatment of Spinal Cord Injury

Uchida, K., Nakajima, H., Guerrero, A. R., Johnson, W. E., Masri, W. E., & Baba, H. (2014) · Therapeutic Delivery · doi:10.4155/tde.14.20 · Cited by 18

Pharmacologically active microcarriers for endothelial progenitor cell support and survival

Musilli, C., Karam, J., Paccosi, S., Muscari, C., Mugelli, A., Montero‐Menei, C. N., & Parenti, A. (2012) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2012.04.014 · Cited by 18

A microfluidic platform to study the effects of GDNF on neuronal axon entrapment

Wang, Z. Z., Wood, M. D., Mackinnon, S. E., & Sakiyama‐Elbert, S. E. (2018) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2018.08.002 · Cited by 18

Targeting delivery in Parkinson's disease

Newland, B., Dunnett, S. B., & Dowd, E. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.06.003 · Cited by 17

Unraveling the role of glial cell line–derived neurotrophic factor in the treatment of Parkinson’s disease

Kakoty, V., Sarathlal, K. C., Kaur, P., Wadhwa, P. K., Vishwas, S., Khan, F. R., Alhazmi, A. Y., Almasoudi, H. H., Gupta, G., Chellappan, D. K., et al. (2023) · Neurological Sciences · doi:10.1007/s10072-023-07253-2 · Cited by 16

Chronic delivery of α-melanocyte-stimulating hormone in rat hypothalamus using albumin-alginate microparticles: Effects on food intake and body weight

Lucas, N., Legrand, R., Breton, J., Déchelotte, P., Edwards‐Lévy, F., & Fetissov, S. O. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2015.01.037 · Cited by 16

Cryogel microcarriers for sustained local delivery of growth factors to the brain

Hakami, A., Narasimhan, K., Comini, G., Thiele, J., Werner, C., Dowd, E., & Newland, B. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.03.023 · Cited by 15

Nanoformulation: A Useful Therapeutic Strategy for Improving Neuroprotection and the Neurorestorative Potential in Experimental Models of Parkinson's Disease

Lafuente, J. V., Requejo, C., Carrasco, A., & Bengoetxea, H. (2017) · International review of neurobiology · doi:10.1016/bs.irn.2017.09.003 · Cited by 14

Nanodelivery of therapeutic agents in Parkinson's disease

Lafuente, J. V., Requejo, C., & Ugedo, L. (2019) · Progress in brain research · doi:10.1016/bs.pbr.2019.03.004 · Cited by 14

Hydrogels for brain repair: application to Parkinson’s disease

Campo-Montoya, R. D., Luquín, M. R., Puerta, E., Garbayo, E., & Blanco‐Prieto, M. J. (2022) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2022.2136161 · Cited by 14

Development and characterization of polo-like kinase 2 loaded nanoparticles-A novel strategy for (serine-129) phosphorylation of alpha-synuclein

Rodríguez‐Nogales, C., Garbayo, E., Martínez-Valbuena, I., Sebastián, V., Luquín, M. R., & Blanco‐Prieto, M. J. (2016) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2016.06.044 · Cited by 14

Glial Cell Line-Derived Neurotrophic Factor-Transfected Placenta-Derived Versus Bone Marrow-Derived Mesenchymal Cells for Treating Spinal Cord Injury

Lu, Y., Gao, H., Zhang, M., Chen, B., & Yang, H. (2017) · Medical Science Monitor · doi:10.12659/msm.902754 · Cited by 14

In situ injectable hydrogels for spinal cord regeneration: advances from the last 10 years

Morgado, P. I., Palacios, M., & Larraı́n, J. (2019) · Biomedical Physics & Engineering Express · doi:10.1088/2057-1976/ab52e8 · Cited by 14

Xenogeneic delivery of therapeutic products using transient immunosuppression

Park, K. (2009) · Journal of Controlled Release · doi:10.1016/j.jconrel.2009.06.001

Is apoptosis involved in the nigral neuronal death in Parkinson's disease?

Sugita, Y., & Mizuno, Y. (1998) · Pathophysiology · doi:10.1016/s0928-4680(98)81201-7

Striatal implantation of GDNF releasing biodegradable microspheres promotes recovery of motor function in a partial model of Parkinson's disease

Jollivet, C., Aubert‐Pouëssel, A., Clavreul, A., Venier‐Julienne, M., Remy, S., Montero‐Menei, C. N., Benoît, J., & Meneï, P. (2003) · Biomaterials · doi:10.1016/s0142-9612(03)00601-x · Cited by 103

Protection of dopaminergic nigrostriatal afferents by GDNF delivered by microspheres in a rodent model of Parkinson's disease

Gouhier, C., Chalon, S., Aubert‐Pouëssel, A., Venier‐Julienne, M., Jollivet, C., Benoît, J., & Guilloteau, D. (2002) · Synapse · doi:10.1002/syn.10063 · Cited by 41

Long-term effect of intra-striatal glial cell line-derived neurotrophic factor-releasing microspheres in a partial rat model of Parkinson's disease

Jollivet, C., Aubert-Pouessel, A., Clavreul, A., Venier-Julienne, M.-C., Montero-Menei, C. N., Benoit, J.-P., & Menei, P. (2004) · Neuroscience Letters · doi:10.1016/j.neulet.2003.11.051 · Cited by 43